However, other research has reported that long-term using of the ferroptosis inducer erastin can promote HSPB1 expression in cervical cancer cells, which reduces lipid ROS and iron accumulation, and thus leads to erastin resistance. This evidence concerns the gene HSPB1 and cervical carcinoma.